Biogen (BIIB) PT Raised to $381 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $219.88 -1.32%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on Biogen (NASDAQ: BIIB) to $381.00 (from $363.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biogen reports 52-week phase 2 data for lupus skin drug litifilimab
- Macquarie Upgrades Merdeka Copper Gold Tbk PT (MDKA:IJ) to Outperform
- PT Vale Indonesia Tbk (INCO:IJ) (PTNDF) PT Lowered to IDR5,600 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
